"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Descriptor ID |
D004311
|
MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 4 | 4 |
1996 | 0 | 3 | 3 |
1997 | 0 | 9 | 9 |
1998 | 0 | 9 | 9 |
1999 | 0 | 1 | 1 |
2000 | 0 | 3 | 3 |
2001 | 0 | 5 | 5 |
2002 | 0 | 8 | 8 |
2003 | 0 | 10 | 10 |
2004 | 0 | 11 | 11 |
2005 | 0 | 12 | 12 |
2006 | 0 | 7 | 7 |
2007 | 0 | 10 | 10 |
2008 | 0 | 13 | 13 |
2009 | 0 | 13 | 13 |
2010 | 0 | 15 | 15 |
2011 | 0 | 8 | 8 |
2012 | 0 | 12 | 12 |
2013 | 0 | 11 | 11 |
2014 | 0 | 9 | 9 |
2015 | 0 | 21 | 21 |
2016 | 0 | 15 | 15 |
2017 | 0 | 19 | 19 |
2018 | 0 | 22 | 22 |
2019 | 0 | 17 | 17 |
2020 | 0 | 23 | 23 |
2021 | 0 | 14 | 14 |
2022 | 0 | 6 | 6 |
2024 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial. Neurourol Urodyn. 2024 Nov; 43(8):2290-2299.
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
NRG-CC004 ancillary data study-exploring the effect of bupropion on sexual desire in female cancer survivors with and without vulvovaginal symptoms. J Sex Med. 2024 08 01; 21(8):709-715.
-
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug; 35(8):728-738.
-
Heartbeat-evoked neural response abnormalities in generalized anxiety disorder during peripheral adrenergic stimulation. Neuropsychopharmacology. 2024 Jul; 49(8):1246-1254.
-
Bicephalic Transcranial Direct-Current Stimulation Does Not Add Benefits to a Footdrop Stimulator for Improving Functional Mobility in People With Chronic Hemiparesis After Stroke: A Double-Blind, Randomized Controlled Trial. Phys Ther. 2022 08 04; 102(8).
-
Fill levels, cost comparisons, and expulsion force requirements of commonly used topical ophthalmic steroids. J Cataract Refract Surg. 2022 Apr 01; 48(4):475-480.
-
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
-
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.